US Stocks
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc (SUPN)


  • $







Key Stats

Today Low/High$29.47 / $30.11
52 Week Low/High$17.2 / $34.29
P/E ratio16.29
Market Cap$1.6B

Company Details

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations ("on-off" episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.
OrganisationSupernus Pharmaceuticals Inc
HeadquatersRockville, Maryland, US
IndustryHealth Technology
CEOJack Khattar

Discover more

Frequently Asked Questions

What is Supernus Pharmaceuticals Inc (SUPN) share price today?

Can Indians buy Supernus Pharmaceuticals Inc (SUPN) shares?

How can I buy Supernus Pharmaceuticals Inc (SUPN) shares from India?

Can Fractional shares of Supernus Pharmaceuticals Inc (SUPN) be purchased?

What are the documents required to start investing in Supernus Pharmaceuticals Inc (SUPN) stocks?

We are a SEBI registered investement advisor